Steven K H Foung
Overview
Explore the profile of Steven K H Foung including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
69
Citations
2719
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
Desombere I, Mesalam A, Urbanowicz R, Van Houtte F, Verhoye L, Keck Z, et al.
Antiviral Res
. 2017 Oct;
148:53-64.
PMID: 29074219
Conclusion: mAb 2A5 shows potent anti-HCV neutralizing activity both in vitro and in vivo and could hence represent a valuable candidate to prevent HCV recurrence in LT-patients. In addition, the...
22.
Vasiliauskaite I, Owsianka A, England P, Khan A, Cole S, Bankwitz D, et al.
mBio
. 2017 May;
8(3).
PMID: 28512091
The hepatitis C virus (HCV) glycoprotein E2 is the major target of neutralizing antibodies and is therefore highly relevant for vaccine design. Its structure features a central immunoglobulin (Ig)-like β-sandwich...
23.
Pierce B, Keck Z, Lau P, Fauvelle C, Gowthaman R, Baumert T, et al.
Proc Natl Acad Sci U S A
. 2016 Oct;
113(45):E6946-E6954.
PMID: 27791171
The E2 envelope glycoprotein is the primary target of human neutralizing antibody response against hepatitis C virus (HCV), and is thus a major focus of vaccine and immunotherapeutics efforts. There...
24.
Keck Z, Wang Y, Lau P, Lund G, Rangarajan S, Fauvelle C, et al.
Hepatology
. 2016 Sep;
64(6):1922-1933.
PMID: 27641232
Conclusion: The findings suggest that a single broadly neutralizing antibody can prevent acute HCV infection without inducing RAVs and may complement DAAs to reduce the emergence of RAVs. (Hepatology 2016;64:1922-1933).
25.
Prentoe J, Velazquez-Moctezuma R, Foung S, Law M, Bukh J
Hepatology
. 2016 Jun;
64(6):1881-1892.
PMID: 27351277
Conclusion: HVR1 adds complexity to HCV neutralization by shielding a diverse array of unexpectedly cross-genotype-conserved E1/E2 epitopes. Thus, an HVR1-deleted antigen could be a better HCV vaccine immunogen. (Hepatology 2016;64:1881-1892).
26.
Fauvelle C, Colpitts C, Keck Z, Pierce B, Foung S, Baumert T
Expert Rev Vaccines
. 2016 Jun;
15(12):1535-1544.
PMID: 27267297
With more than 150 million chronically infected people, hepatitis C virus (HCV) remains a substantial global health burden. Direct-acting antivirals have dramatically improved viral cure. However, limited access to therapy,...
27.
Howell K, Qiu X, Brannan J, Bryan C, Davidson E, Holtsberg F, et al.
Cell Rep
. 2016 May;
15(7):1514-1526.
PMID: 27160900
Previous efforts to identify cross-neutralizing antibodies to the receptor-binding site (RBS) of ebolavirus glycoproteins have been unsuccessful, largely because the RBS is occluded on the viral surface. We report a...
28.
Keck Z, Girard-Blanc C, Wang W, Lau P, Zuiani A, Rey F, et al.
J Virol
. 2016 Jan;
90(6):3112-22.
PMID: 26739044
Unlabelled: Hypervariable region 1 (HVR1) (amino acids [aa] 384 to 410) on the E2 glycoprotein of hepatitis C virus contributes to persistent infection by evolving escape mutations that attenuate binding...
29.
Keck Z, Enterlein S, Howell K, Vu H, Shulenin S, Warfield K, et al.
J Virol
. 2015 Oct;
90(1):279-91.
PMID: 26468532
Unlabelled: Filoviruses cause highly lethal viral hemorrhagic fever in humans and nonhuman primates. Current immunotherapeutic options for filoviruses are mostly specific to Ebola virus (EBOV), although other members of Filoviridae...
30.
Fauvelle C, Felmlee D, Crouchet E, Lee J, Heydmann L, Lefevre M, et al.
Gastroenterology
. 2015 Sep;
150(1):206-217.e4.
PMID: 26404951
Background & Aims: Efforts to develop an effective vaccine against hepatitis C virus (HCV) have been hindered by the propensity of the virus to evade host immune responses. HCV particles...